Pancreatic cancer is one of the most aggressive and difficult-to-treat cancers. One reason for its resistance to therapy is the dense tissue surrounding the tumor that acts as a protective barrier and suppresses the immune ...
Oct 23, 2026
0
84
In a world-first international trial, adding intismeran, a type of personalized therapeutic cancer vaccine made from each patient's own tumor, to pembrolizumab immunotherapy after surgery for high-risk melanoma reduced the ...
Oct 23, 2026
0
27
A new prospective study from Japan explored whether fish consumption before and during pregnancy is linked to hypertensive disorders of pregnancy, including gestational hypertension and preeclampsia. Researchers analyzed ...
Oct 23, 2026
0
12
A kind attitude toward oneself and practicing mindfulness can improve functioning in individuals who experience severe premenstrual symptoms, according to a study by psychologists from SWPS University and Jagiellonian University.
Oct 23, 2026
0
22
Research published today identifies potential new ways to treat the most common type of colorectal cancer in Ireland. The study, conducted by an international research team led by RCSI University of Medicine and Health Sciences ...
Oct 23, 2026
0
9
About 10% of cancers are linked to an inherited genetic variant, but as few as one in 15 cancer patients eligible for genetic testing complete it.
Oct 23, 2026
0
7
An overlooked mechanism in lung cancer tumors may help explain why most patients don't respond to immunotherapy, according to new research led by Olga Anczuków, professor at The Jackson Laboratory for Genomic Medicine in ...
Oct 23, 2026
0
9
Clinician-scientists hope to expand the use of blood-based biomarker tests for traumatic brain injury (TBI) to improve identification and escalation of care for patients whose diagnosis otherwise might be missed.
Oct 23, 2026
0
17
For patients with moderately to severely active ulcerative colitis, oral icotrokinra, a peptide that blocks the interleukin-23 receptor, yields a clinical response at week 12 significantly more often than placebo, according ...
Oct 23, 2026
0
15
The phase 2 BESTOW clinical trial showed that tegoprubart (a novel anti-CD40L antibody therapy) was better at preserving kidney function than tacrolimus (the current standard of care) in immunosuppressive regimens in adults ...
Oct 23, 2026
0
13
